Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis
Yueying Chen, Yanjun Du, Juan Ni, Dong Wang, Ping Zhan, Yong Song, Hedong Han, Tangfeng Lv · 2025
Read Antibody-drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC: a Bayesian network meta-analysis by Yueying Chen, Yanjun Du, Juan Ni, Dong Wang, Ping Zhan, Yong Song, Hedong Han, Tangfeng Lv (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12709029.txt.
Description
Yueying Chen and seven co-authors compare lung cancer treatments in a 2025 analysis. Some lung cancers resist the targeted pills aimed at a mutated growth receptor. Antibody drug conjugates, which ferry poison straight to tumor cells, are a newer option. The team weighed them against chemotherapy and other regimens after resistance sets in.
Nineteen randomized trials with over four thousand patients entered the pool. A Bayesian network method ranked the options by survival gains. One conjugate led clearly on both delay of growth and overall survival. Rankings of combined scores confirmed its edge over plain chemotherapy. Safety profiles were weighed alongside benefit. The authors name the leading conjugate the current best choice. Larger head to head trials could still shift the ranking.
Catalog record
| CREATOR | Yueying Chen, Yanjun Du, Juan Ni, Dong Wang, Ping Zhan, Yong Song, Hedong Han, Tangfeng Lv |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |